Apellis Pharmaceuticals Stock (NASDAQ: APLS)

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

APLS

Analyst Color

Biotech

Earnings

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

JP Morgan sees Apellis&#39; Syfovre as a potential $1.5B drug. Empaveli&#39;s approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Markets

CELC

EVCM

EVGO

INVX

MAMA

MNSO

PSBD

RCAT

Mama&#39;s Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Analysts

Downgrades

Pre-Market Outlook

COMM

EXEL

MTCH

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals Inc

Press Releases

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

Apellis Announces Keli Walbert to Join the Board of Directors

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Legal

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

CART

MGNX

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Amicus Therapeutics

Immunovant

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

JP Morgan

RBC Capital

Goldman Sachs

Wedbush

HC Wainwright & Co.

Comments

Apellis Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga